Background: Children with asthma living in highly polluted megacities are at increased risk of poor asthma control and airway inflammation. Breastfeeding has immunomodulatory effects, but its potential to buffer pollution‐related inflammation remains understudied. Objective: To evaluate whether breastfeeding duration is associated with asthma control and airway eosinophilic inflammation (FeNO), and whether it modifies the impact of urban air pollution in children with asthma living in Mexico City. Methods: We conducted a multicenter retrospective study (2022–2025) including children aged 6–17 years with physician‐diagnosed asthma. Asthma control (ACT), airway inflammation (FeNO, NIOX VERO), breastfeeding duration (0–12 months), and borough‐level pollution categories (high/medium/low) were evaluated. Multivariable logistic and linear regression models assessed associations and breastfeeding × pollution interactions. Results: A total of 162 children were included (mean age 10.8 years; 51.2% female). Breastfeeding ≥ 6 months was associated with better asthma control (ACT ≥ 20: OR 2.1; 95% CI 1.3–3.5) and significantly lower FeNO (β −0.24; p < 0.01). High‐pollution residence was linked to lower ACT scores and higher FeNO (both p < 0.01). A significant interaction indicated that breastfeeding ≥ 6 months attenuated the detrimental effect of pollution on airway inflammation and asthma control ( p for interaction < 0.05). Conclusions: Prolonged breastfeeding was independently associated with improved asthma control and reduced airway eosinophilic inflammation, partially mitigating the respiratory burden of chronic pollution exposure. Clinical Implications: Breastfeeding may serve as an accessible, low‐cost protective strategy for children with asthma living in polluted urban environments, supporting its integration into respiratory health policies and early‐life preventive care.
28 October 2025 in Memorias del Concurso Lasallista de Investigación, Desarrollo e innovación
Se investigó la frecuencia y características clínicas de pacientes asmáticos tratados con terapia triple ICS/LABA/LAMA en centros especializados en asma en América Latina. Se recopilaron datos sociodemo-gráficos, fenotípicos y clínicos de 279 pacientes con asma que recibieron tratamiento en pasos 4 y 5 según GINA, durante al menos un año. Se compararon los resultados clínicos entre quienes recibieron LAMA y quienes no. Se encontró que los pacientes en paso 4 que recibieron ICS/LABA/LAMA mostraron mejor control del asma, mientras que en paso 5, el control fue menor debido a la severidad del cuadro clínico, priorizándose el uso de terapias biológicas. Los hallazgos sugieren que la adición de LAMA puede mejorar el control del asma en pacientes con enfermedad moderada, independientemente de las características fenotípicas. Este estudio aporta evidencia real de centros especializados sobre el uso efectivo de la terapia triple en el manejo del asma moderada a severa.